Health systems need to use the new tools to address RSV, a leading cause of baby hospitalisations
From being a largely unknown pathogen, Respiratory Syncytial Virus (RSV) is now almost a household word – and a fearful one for families with infants and young children at risk. But new solutions, such as long-acting monoclonal antibodies (mAbs) and maternal vaccination, both recently recommended by the World Health Organization (WHO), could dramatically alter the […]
Continue reading ->
Health Policy Watch. (2024, December 8). New tools to address RSV, a leading cause of baby hospitalisations. Health Policy Watch. https://healthpolicy-watch.news/new-tools-to-address-rsv-a-leading-cause-of-baby-hospitalisations/
Related news
Julius Clinical Celebrates Major GRIPonMASH Milestone
The GRIPonMASH consortium has reached a significant milestone in screening individuals at risk of metabolic dysfunction-associated steatotic liver disease (MASLD). Julius Clinical is proud to contribute to this achievement.The GRIPonMASH conso...
P95 and Julius Clinical Merge to Form Global, Science-Led CRO Delivering Integrated Clinical Development and Real-World Evidence
500+ person global organization spans 25+ countries with operations across North America, Europe, Africa, Latin America, and Asia-Pacific
Julius Clinical Welcomes Bassem Saleh as Chief Executive Officer
Zeist, The Netherlands – September 23, 2025 – Julius Clinical, a leading clinical Contract Research Organization (CRO) with deep therapeutic expertise in CNS and Cardiometabolic diseases, is pleased to announce the appointment of Bassem Saleh ...